Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

Journal article

Authors: Sørensen, P; Deisenhammer, F; Duda, P; Hohlfeld, R; Myhr, K

• Publisher: Wiley-Blackwell
• Volume: 1
• Pages: 63-74
• Publication date: 2010-09-06
• DOI: 10.1002/9781444328394.ch5
• Language: English
• Keywords: Interferon (IFN) β, first-line therapy for relapsing-remitting multiple sclerosis (MS); Methods used for BAB detection-ELISA method, Western Blot (WB) method and radio-immunoprecipitation (RIPA) or affinity chromatography (ACA) assays; Plasmapheresis and immunoglobulins (IgG)-possible procedures to diminish NAB generation; Binding antibodies (BABs) and neutralizing antibodies (NABs)-occurring during treatment with recombinant IFN β products; Advantage of affinity chromatography assay (ACA) and radio-immunoprecipitation assay (RIPA), that antigen is in solution; Immunogenicity of recombinant IFN β-to be most influenced by formulation itself; Dynamics of NABs; Frequency of NAB-positive patients in initial pivotal placebo-controlled trials; Use of anti-interferon beta antibody measurements-in multiple sclerosis; Measurements of binding and neutralizing antibodies